AstraZeneca is trading 3.00% up at $173.51 after the FDA granted accelerated U.S. approval for Ultomiris to reduce proteinuria in adults with primary IgA nephropathy.

  • Interim Phase III results showed a 43.4% reduction in proteinuria versus placebo at 34 weeks.
  • The ongoing trial will assess kidney-function outcomes. Broader healthcare sentiment was positive, but major U.S. indexes were lower, leaving the approval as the clearest company-specific explanation.